Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

JBCHEPHARM's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 3.041000
forwardPE 27.557678
debtToEquity 0.812000
earningsGrowth 0.137000
revenueGrowth 0.102000
grossMargins 0.663970
operatingMargins 0.189580
trailingEps 41.540000
forwardEps 0.000000

JBCHEPHARM's current ratio 3.041, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, JBCHEPHARM can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
JBCHEPHARM's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
JBCHEPHARM's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as JBCHEPHARM's increasing profits and sales signal further growth in the near future.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

Over time, J. B. Chemicals & Pharmaceuticals Limited's price projections have consistently been revised lower. This downward shift suggests analysts are becoming more cautious about the company's future, possibly due to emerging risks or challenges.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


42 JBCHEPHARM shares were sold in recent transactions, with market price at 1787.6178617931548.No sell transactions occurred during the period under consideration.More buys than sells near the current price levels of JBCHEPHARM might signal a favorable outlook for the stock. Investors seem to be showing confidence by purchasing more, potentially expecting positive future performance.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


JBCHEPHARM has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see JBCHEPHARM as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.